Class Action Settlement Offers Payments for Hetero, Aurobindo, and Vivimed Drug Purchases
In a recent development regarding class action lawsuits, individuals or entities that made retail purchases of Hetero Valsartan, Aurobindo Irbesartan, or Vivimed Losartan medications between January 1, 2016, and the present day may be eligible for monetary compensation through various settlements. This announcement, approved by the U.S. District Court for the District of New Jersey, is a resolution to claims based on the economic losses incurred by consumers due to these medications, which allegedly contained harmful impurities. The core of the lawsuit asserts that certain batches of these drugs were manufactured with active pharmaceutical ingredients (APIs) contaminated by substances believed to be carcinogenic, including NDMA (N-Nitrosodimethylamine), NDEA (N-Nitrosodiethylamine), and NMBA (N-Nitrosomorpholine). The manufacturers—Hetero Drugs, Aurobindo Pharma, and Vivimed Life Sciences—affirmed that they deny any wrongdoing and maintain that the levels of these contaminants are not harmful. The U.S. District Court has not made a judgment regarding the merit of these claims.
The settlements concern specific medications: Hetero Valsartan sold between May 1, 2018, and July 31, 2018, Losartan formulations from Vivimed with designated National Drug Codes, and Irbesartan produced by Aurobindo purchased from January 1, 2016, to now. The total financial settlements announced involve significant amounts, including more than $11 million from Hetero, $2 million from Aurobindo, and almost $2 million from Vivimed.
To benefit from these settlements, affected consumers must submit a claim form before June 2, 2026. This can be done online or through a paper form submitted via mail, and the claim may necessitate supporting documentation depending on the situation. It's crucial for people to act swiftly since failure to submit a claim will mean no compensation and the relinquishing of the right to pursue further legal action. Conversely, opting out of the settlement allows individuals to retain their right to sue the manufacturers but will eliminate the chance of receiving compensation from the settlement itself.
In addition to the claim options, affected parties can choose to object to the settlements, providing their grievances to the Court. However, they must maintain their status as class members to do so. Detailed procedures for filing claims, opting out, or expressing objections are available on the settlement’s official website: www.SartanMedicationSettlement.com.
This information aims to empower consumers who have purchased the affected medications to take necessary actions towards compensation. Affected individuals should evaluate their options carefully and consider the implications on their legal rights.
For further assistance, class members can seek guidance from appointed legal representatives involved in the case. This development marks a significant moment for those seeking recourse in light of their experiences with these medications, emphasizing the importance of consumer awareness in medication safety and regulatory practices. More information about this class action can be obtained through the official resources provided in the settlement notice.
The settlements concern specific medications: Hetero Valsartan sold between May 1, 2018, and July 31, 2018, Losartan formulations from Vivimed with designated National Drug Codes, and Irbesartan produced by Aurobindo purchased from January 1, 2016, to now. The total financial settlements announced involve significant amounts, including more than $11 million from Hetero, $2 million from Aurobindo, and almost $2 million from Vivimed.
What You Need to Know
To benefit from these settlements, affected consumers must submit a claim form before June 2, 2026. This can be done online or through a paper form submitted via mail, and the claim may necessitate supporting documentation depending on the situation. It's crucial for people to act swiftly since failure to submit a claim will mean no compensation and the relinquishing of the right to pursue further legal action. Conversely, opting out of the settlement allows individuals to retain their right to sue the manufacturers but will eliminate the chance of receiving compensation from the settlement itself.
In addition to the claim options, affected parties can choose to object to the settlements, providing their grievances to the Court. However, they must maintain their status as class members to do so. Detailed procedures for filing claims, opting out, or expressing objections are available on the settlement’s official website: www.SartanMedicationSettlement.com.
This information aims to empower consumers who have purchased the affected medications to take necessary actions towards compensation. Affected individuals should evaluate their options carefully and consider the implications on their legal rights.
For further assistance, class members can seek guidance from appointed legal representatives involved in the case. This development marks a significant moment for those seeking recourse in light of their experiences with these medications, emphasizing the importance of consumer awareness in medication safety and regulatory practices. More information about this class action can be obtained through the official resources provided in the settlement notice.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.